These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410 [TBL] [Abstract][Full Text] [Related]
13. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951). Haberkorn BC; Eskens FA Future Oncol; 2013 Jan; 9(1):13-20. PubMed ID: 23252559 [TBL] [Abstract][Full Text] [Related]
14. [Drug now immediately available in Germany]. Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396 [No Abstract] [Full Text] [Related]
15. The end of chemotherapy in renal cell carcinoma: for much but not for all. Iacovelli R; Raimondi C; Palazzo A Am J Clin Oncol; 2010 Oct; 33(5):522-3. PubMed ID: 20924226 [No Abstract] [Full Text] [Related]
17. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Flaherty KT; Puzanov I Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128 [TBL] [Abstract][Full Text] [Related]
19. Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Shepard DR; Garcia JA Expert Rev Anticancer Ther; 2009 Jun; 9(6):795-805. PubMed ID: 19496716 [TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. Mulders P BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]